Clinical Trials Logo
  1. Home
  2. Covid19
  3. NCT05465759
  4. Details
NCT05465759 Clinical Trial

Frequency of SARS COVID-19 Infection Among Malignant Patients at South Egypt Cancer Institute

COVID-19 Clinical Trial

Official title:
Frequency of SARS COV-2 Infection Among Malignant Patients at South Egypt Cancer Institute

Clinical Trial Details — Status: Not yet recruiting

Administrative data
NCT number NCT05465759
Other study ID # COVID-19 in cancer patients
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date July 2022
Est. completion date August 2023

Study information
Verified date July 2022
Source Assiut University
Contact mahmoud ahmed agamy, post graduate
Phone 01017989744
Email mahmoudahmedatm@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Assessment the frequency of SARS COV-2 infection among malignant patients at south Egypt Cancer institute

Description:

Coronavirus disease (COVID-19) is an infectious disease caused by the SARS-CoV-2 virus Most people infected with the virus will experience mild to moderate respiratory illness and recover without requiring special treatment. However, some will become seriously ill and require medical attention. Older people and those with underlying medical conditions like cardiovascular disease, diabetes, chronic respiratory disease, or cancer are more likely to develop serious illness. Anyone can get sick with COVID-19 and become seriously ill or die at any age Cancer is one of the most common examples of immunocompromised states

Recruitment information / eligibility
Status Not yet recruiting
Enrollment 200
Est. completion date August 2023
Est. primary completion date July 2023
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Malignant patients. - PCR positive for covid-19 Exclusion Criteria: - PCR negative for covid-19

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• disease
Frequency of SARS COV-2 infection among malignant patients at south Egypt Cancer institute.

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Assiut University

Outcome
Type Measure Description Time frame Safety issue
Primary calculate the frequency of SARS-CoV-2 infection among patients with malignant data collection during the study period To calculate the rate of SARS-CoV-2 infection among patients with malignant data collection within covid-19 pandemic either retrospective or prospective.
Data will include :
patient demography such as Age,sex,smoking status,cancer type cancer treatment (patient on chemotherapy or radiotherapy if available), symptoms, signs and laboratory parameters of COVID -19. outcome including hospitalization or ICU admission and mortality rate will be recorded		 1 year
See also
  Status Clinical Trial Phase
Withdrawn NCT06065033 - Exercise Interventions in Post-acute Sequelae of Covid-19 N/A
Completed NCT06267534 - Mindfulness-based Mobile Applications Program N/A
Completed NCT05047601 - A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection Phase 2/Phase 3
Recruiting NCT05323760 - Functional Capacity in Patients Post Mild COVID-19 N/A
Recruiting NCT04481633 - Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection N/A
Completed NCT04537949 - A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults Phase 1/Phase 2
Completed NCT04612972 - Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru Phase 3
Recruiting NCT05494424 - Cognitive Rehabilitation in Post-COVID-19 Condition N/A
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Enrolling by invitation NCT05589376 - You and Me Healthy
Completed NCT05158816 - Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
Recruiting NCT04341506 - Non-contact ECG Sensor System for COVID19
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Completed NCT05975060 - A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. Phase 2/Phase 3
Active, not recruiting NCT05542862 - Booster Study of SpikoGen COVID-19 Vaccine Phase 3
Withdrawn NCT05621967 - Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation N/A
Terminated NCT05487040 - A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease Phase 1
Terminated NCT04498273 - COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 Phase 3
Active, not recruiting NCT06033560 - The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure